Research Areas

Biomarker Research
Diagnostic, Genomic Biomarker

At a Glance

- Status: Completed Consortium
- Year Launched: 2010
- Initiating Organization: Innovative Medicines Initiative
- Initiator Type: Government
- Location: Europe

Abstract

A complete or relative decrease in insulin secretion by pancreatic beta cells underlies the development of, respectively, Type 1 and Type 2 diabetes. Largely because of limited knowledge of beta-cell biology in health and disease, symptomatic therapeutic options for treatment of diabetes are available, but none cure or prevent this pandemic disease. Although considerable knowledge has been gained on the function of beta cells from animal models, knowledge of human beta-cell function, survival, and the pathophysiological mechanisms that lead to their demise remains limited. The “Improving beta-cell function and identification of diagnostic biomarkers for treatment monitoring in Diabetes” (IMIDIA) project brings together academic teams, pharmaceutical companies, and a small to medium-sized enterprise, which provides a unique blend of expertise and forms a strong basis for a successful enterprise to ultimately improve industrial competitiveness and public health in Europe. The expected duration of the project is 60 months.

Mission

IMIDIA aims at delivering the following:
• Novel tools for the study of human pancreatic beta-cell development, function and survival, their modulation by potential therapeutic compounds and for in vivo beta-cell imaging
• Biomarker for diagnosis and prognosis of beta-cell failure and for monitoring diabetes progression and success of disease treatment
• Knowledge on novel pathways and sites that control beta-cell proliferation, differentiation and apoptosis, and on the role of nutrient-regulated pathways and sites in controlling beta-cell mass and function

Consortium History

Jan. 2, 2010: Project launched
June 14-15, 2010: IMI Stakeholder Forum took place
2013: IMIDIA organized a satellite symposium of the consortia of the IMI Diabetes Platform at the European Association for the Study of Diabetes meeting in Barcelona

Structure & Governance

Coordination Team Members:
Servier: A. Ktorza

Project Coordinator
W. Kramer
Sanofi-Aventis GmbH
Frankfurt, Germany

Managing Entity of IMI Beneficiaries
Bernard Thorens
Department of Physiology & Center for Integrative Genomics
Université de Lausanne
Lausanne, Switzerland
Financing

This project is funded by the Innovative Medicines Initiative (IMI), a public-private partnership between the European Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA), resources of which consist of financial contribution from the European Union Seventh Framework Programme and EFPIA companies’ in kind contribution. Large pharmaceutical companies participating in IMI projects do not receive IMI funding.

Contributions consist of €7.0 million from IMI, €15.1 million in kind from EFPIA, and €3.8 million from other sources, for a total cost of €25.9 million.

Intellectual Property

The IMI intellectual property (IP) policy governs the IP regime of all projects funded by the IMI Joint Undertaking. To assist with specific IP queries, IMI has set up a dedicated IP Helpdesk, which can be contacted by emailing IMI-IP-Helpdesk@imi.europa.eu. The IMI IP policy can be accessed at http://www.imi.europa.eu/sites/default/files/uploads/documents/imi-ipr-policy01august2007_en.pdf

Data Sharing

According to IMI’s IP policy, participants undertake to disseminate the data as soon as reasonably practicable but not later than one year after the termination or expiry of the project. The project agreement shall include a description of the material that must be disseminated in accordance with the IP policy and referenced in the grant agreement. If participants do not disseminate within such time periods without good reason, then the Executive Office has the right to disseminate such results in a manner consistent with the grant agreement.

Impact/Accomplishment

The list of publications by IMIDIA members can be found at http://www.imidia.org/publications/imidia-members.php
The list of IMIDIA-derived publications can be found at http://www.imidia.org/publications/imidia-derived.php

Links/Social Media Feed

Homepage: http://www.imidia.org/
Other website: http://www.imi.europa.eu/content/imidia

Points of Contact

contact@imidia.org

Sanofi-Aventis GmbH
Frankfurt, Germany

Bernard Thorens
Department of Physiology & Center for Integrative Genomics
Université de Lausanne
Lausanne, Switzerland

Sponsors & Partners

AstraZeneca AB
Boehringer Ingelheim International GmbH
Centre National de la Recherche Scientifique (CNRS)
Commissariat à l’Energie Atomique
Eli Lilly Ltd., Basingstoke
Endocells SARL
F. Hoffmann-La Roche AG
Imperial College of Science, Technology and Medicine
Institut De Recherches Servier
Institut National de la Santé et de la Recherche Medicale (INSERM)
Institut Suisse de Bioinformatique
Medizinische Hochschule Hannover
Novartis Pharma AG
Novo Nordisk A/S
Sanofi-Aventis GmbH
Technische Universität Dresden
Universita di Pisa
Université de Geneve
Université de Lausanne
Université Paris Diderot - Paris 7
Vrije Universiteit Brussel

Updated: 11/20/2017